Another BCMA CAR-T therapy for multiple myeloma hits the market in China! – 🔥Long-term efficacy 🔥

🌎Another BCMA CAR-T therapy for multiple myeloma hits the market in China!

    – 🔥Long-term efficacy 🔥

multiple myeloma

🌙China has made significant breakthroughs in the treatment of multiple myeloma with BCMA CAR-T therapy, attracting global attention. Recently, two fully human BCMA CAR-T therapies, Equecabtagene Autoleucel and Zevorcabtagene Autoleucel, have been approved for the treatment of relapsed/refractory multiple myeloma.⭐️

🌛 In terms of long-term efficacy, for patients with a CAR-T cell persistence of over one year, the percentage is 53.3% for Equecabtagene Autoleucel and 26.5% for Zevorcabtagene Autoleucel at six months’ persistence.⭐️

🌜The duration of CAR-T cell persistence has an impact on the survival outcome of multiple myeloma (MM) patients. Long-term follow-up data from the Lengend-2 study showed a significant improvement in the cumulative overall survival (OS) rate for RRMM patients with a CAR-T cell persistence of over 280 days compared to patients with a persistence of less than 280 days. Therefore, 280 days of persistence is a critical threshold for improving clinical outcomes.⭐️

✨The median persistence for Zevorcabtagene Autoleucel is 77 days, while for Equecabtagene Autoleucel, it is 419 days, far exceeding the critical threshold. It is expected to improve the OS of MM patients.⭐️

🌤From a clinical perspective, both therapies demonstrate a trend of improving long-term efficacy over time.

The complete response (CR) rate at six months of follow-up is 54.8% for Equecabtagene Autoleucel and 35.0% for Zevorcabtagene Autoleucel.⭐️

🌝At a median follow-up of around nine months, the registered clinical data from China shows a CR rate of ≥74.2% for Equecabtagene Autoleucel and 45.1% for Zevorcabtagene Autoleucel.⭐️

🌞During the 2023 IMS conference, Equecabtagene Autoleucel presented the latest long-term follow-up data, revealing a further increase in the CR rate to 82.4% at a median follow-up of 18.07 months.⭐️

☀️The efficacy data following a median follow-up of nine months for Zevorcabtagene Autoleucel in the registered clinical trial LUMMICAR-1 Phase 2 study has not been publicly disclosed.

China’s breakthroughs in CAR-T cell therapy are remarkable. It not only provides new treatment options for multiple myeloma patients but also demonstrates China’s strength in medical research and innovation. It brings hope and possibilities for improving patients’ survival and quality of life.⭐️

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#BCMACART #MultipleMyeloma #Innovation #CART #CARTTherapy #chinesemedical

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago Myeloma

Another BCMA CAR-T therapy for multiple myeloma hits the market in China! – Short-term efficacy

Another BCMA CAR-T therapy for multiple myeloma hits the market in China!

– Short-term efficacy

multiple myeloma

China  CAR-T therapy

    In recent years, CAR-T cell therapy has achieved tremendous success in treating hematologic malignancies. Over the past 11 years, China has seen a surge in clinical trials evaluating the safety and efficacy of CAR-T therapy. China has now surpassed the United States as a major force in CAR-T clinical research.

In the field of multiple myeloma (MM),

    China has gained regulatory approval from the NMPA for two fully human BCMA CAR-T therapies for the treatment of relapsed/refractory MM (R/R MM). These therapies are Equecabtagene Autoleucel and Zevorcabtagene Autoleucel.

BCMA

    While both therapies target the same BCMA and share a common co-stimulatory domain, there are some fundamental differences between them. Zevorcabtagene Autoleucel includes patients with stable disease after previous treatment, whereas Equecabtagene Autoleucel focuses on patients with relapsed or progressive MM.

Looking at the short-term efficacy

    The median time to peak CAR-T cells in peripheral blood is 12 days for Equecabtagene Autoleucel and 14 days for Zevorcabtagene Autoleucel. This indicates that the former can rapidly exert its effect, potentially laying the foundation for achieving clinical remission faster and better.

Clinical trial results seem to support this notion, with Equecabtagene Autoleucel showing a median time to response (TTR) of 15 days, compared to 29 days for Zevorcabtagene Autoleucel. At the 3-month follow-up, the complete remission rates were 40.3% for Equecabtagene Autoleucel in the registered clinical trial FUMANBA-1 1b/2 phase, surpassing the rate of 28.3% observed in the registered clinical trial LUMMICAR-1 phase 2 for Zevorcabtagene Autoleucel.

It’s worth noting that the infusion dose for Equecabtagene Autoleucel is 1×106 cells/kg, while the total infusion dose for Zevorcabtagene Autoleucel is 150×106 cells, which translates to double the dose of Equecabtagene Autoleucel for patients with a weight of 70kg-75kg. Additionally, the reinfusion dose for Zevorcabtagene Autoleucel is not fixed and needs to be increased to 1.8×108 cells for patients weighing ≥80kg.

With the increasing availability of these groundbreaking BCMA CAR-T therapies, the landscape of multiple myeloma treatment continues to expand, offering more possibilities and choices.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#BCMACART #MultipleMyeloma #Innovation #CART #CARTTherapy #chinesemedical Advanced Medicine in China

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago Myeloma

$160,000 per dose! The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.

🌈 $160,000 per dose! 🌈

⭐The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.

multiple myeloma

Zevor-cel

🌦On March 5th, the fifth approved CAR-T therapy in China, Zevor-cel injection (Zevor-cel) by CARsgen, was priced at $116,000 for its initial release.

Zevor-cel injection is an autologous CAR-T product targeting BCMA. It is the fifth CAR-T therapy approved and marketed in China, following Axicabtagene Ciloleucel by Fosun Kite, Relmacabtagene Autoleucel by JW Therapeutics, Equecabtagene Autoleucel by IASO Bio, and Inaticabtagene Autoleucel by Juventas.

Cheapest CAR-T therapy

🌺Currently, the cheapest approved CAR-T therapy in the world is Inaticabtagene Autoleucel by Juventas. The price has dropped below one million RMB, at 999,000 RMB (equivalent to less than $140,000).

 

US CAR-T

🌼In 2017, the US FDA approved two CAR-T products, marking the beginning of the era of immunocellular therapy. CAR-T therapy has always been known for its high prices. Just how expensive is it? The two CAR-T therapies approved for sale in the United States are priced at $475,000 (Kymriah) and $373,000 (Yescarta), and these are just the prices of the drugs themselves. The total cost of the treatment far exceeds these amounts.

Multiple Myeloma

🌻For the treatment of multiple myeloma, there are currently two CAR-T products on the US market: Idecabtagene vicleucel by BMS/bluebird bio and ciltacabtagene autoleucel by Legend Bio. They are priced at $419,000 and $465,000, respectively, with a BCMA target and a complete response (CR) rate of 28% and 78%.

 

In China

⚡ there are also two CAR-T products on the market: Zevor-cel injection by CARsgen and Equecabtagene Autoleucel injection by IASO Bio. They are priced at $160,000 and $162,000, respectively, with the same BCMA target and CR rates as high as 78.6% and 82.4%.

 

🌤To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp+8613717959070

doctor.huang@globecancer.com

 

#CARTtherapy #CancerTreatment #Immunotherapy #MultipleMyeloma #BCMA #Zevorcel #CARsgen #MedicalBreakthrough #HealthcareInnovation #PrecisionMedicine #PersonalizedMedicine #MedicalAdvancements #FightAgainstCancer #GlobalHealthcare #AffordableMedicine

#CancerResearch #PatientCare #MedicalTechnology #InnovativeTherapy #HopeForPatients

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

9 months ago CAR-T

The domestically researched CAR-T therapy in China significantly increases the remission rate of multiple myeloma patients, with the highest reaching up to 100%!

✨ The domestically researched CAR-T therapy in China significantly increases the remission rate of multiple myeloma patients, with the highest reaching up to 100%! ✨

 

multiple myeloma

🌟BCMA (also known as CD269) and GPRC5D, these two targets are revolutionizing the treatment landscape of multiple myeloma (MM). BCMA is one of the hottest targets for treating MM currently, while GPRC5D is poised to be a potent complement to BCMA.

 

🔍 About BCMA: CAR-T Therapy with Remission Rates Exceeding 90%!

 

👩‍⚕️BCMA is primarily expressed on the surface of terminally differentiated B cells, making it a promising new target in hematologic malignancies treatment. Currently, both in clinical trials and marketed BCMA-targeted CAR-T therapies have shown significant efficacy, with some second-generation CAR-T projects achieving remission rates of over 90%, and the remission rates of domestically produced CAR-T products are also leading globally.

 

Among domestically produced CAR-T therapies in China,

🌟The marketed injection of Cilta-cel (Carvykti) has an overall remission rate of 89.6% and a complete remission rate of 77.1%.

🌟The fully human Equecabtagene Autoleucel injection (developed by the highly regarded Chinese company IASO Bio) boasts an overall remission rate of 98.9%, with a complete remission rate of 82.4%.

🌟Additionally, recent follow-up data from the ASH conference showed that Zevor-cel, developed by Chinese company CARsgen and just approved for market in China, has an overall remission rate of 100%, with a complete remission rate of 92.9%.

 

💡 About GPRC5D: A New Hopeful Treatment Target!

 

🔬About 65% of MM patients exhibit high expression of GPRC5D, and its expression is relatively independent of BCMA. The development speed of domestically produced CAR-T projects in China is considerable. For example, OriCAR-017, a CAR-T product developed by a domestic pharmaceutical company, achieved an overall remission rate of 100% in 10 trial patients, with a strict complete remission rate of 60%.

 

🩺China is rapidly advancing in the field of CAR-T therapy, leading the way in both technological development and clinical applications. In the future, we will witness more “miracles of healing” created by these novel cell therapies.

 

We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.

We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.

doctor.huang@globecancer.com

WhatsApp+8613717959070

 

#MultipleMyeloma #BCMA #GPRC5D #CART #CellTherapy #MiraclesOfHealing #CARTcell

11 months ago CAR-T

Global First: Chinese CAR-T Therapy Simultaneously Cures Tumor and Lupus Erythematosus

China make advanced medical treatment affordable

Wang Fang (pseudonym), residing in Yichang, Hubei, China, underwent a life-threatening ordeal. This patient in her forties had been suffering from systemic lupus erythematosus for over 20 years. What exacerbated her agony was the excruciating pain in her right leg since June 2019, which forced her into a wheelchair. Local hospital diagnosis revealed an aggressively invasive tumor—diffuse large B-cell lymphoma.

 

In mid-August 2019, Wang Fang followed a relative’s advice and sought treatment at Peking University Shenzhen Hospital (hereinafter referred to as “PKU Shenzhen Hospital”) in Shenzhen, where she was fortunate to participate in clinical trials for blood tumors. In mid-September 2019, she underwent the compound dual-target CAR-T (CD19/BCMA) cell immunotherapy.

 

Miraculous changes occurred a month after treatment; her lymphoma vanished entirely. Two months later, she was freed from the wheelchair and could walk independently. The nine-month follow-up, more astonishingly, revealed not only the complete disappearance of lymphoma but also the reversal of her long-standing stubborn lupus erythematosus antibodies, signifying her clinical cure from lupus.

 

This is the first documented instance globally where compound dual-target CAR-T cell immunotherapy cured diffuse large B-cell lymphoma and refractory lupus erythematosus—a significant breakthrough in Shenzhen’s oncology clinical research and treatment field.

 

This patient, originally from another region, had relied on steroids and other drugs to manage her condition for over 20 years due to systemic lupus erythematosus. However, the intensified pain in her right leg in June 2019 led to the diagnosis of an invasive tumor, rapidly deteriorating her condition and confining her to a wheelchair.

 

When faced with chemotherapy recommendations at the local hospital, Wang Fang declined due to the side effects she had previously experienced. Fortunately, a relative’s recommendation brought her to PKU Shenzhen Hospital. With the doctors’ dedicated assistance, Wang Fang participated in the clinical trial of CAR-T cell immunotherapy.

 

CAR-T cell therapy is an advanced treatment method that transforms a patient’s own T cells into CAR-T cells capable of identifying and attacking tumor cells. Since its successful treatment of the first case of acute lymphoblastic leukemia in the United States in 2012, this treatment has gradually become a groundbreaking technology in the field of tumor therapy. The Blood Department of PKU Shenzhen Hospital, as a pioneer, has completed over 30 cases of CAR-T cell therapy clinical trials, offering hope for those patients in critical conditions with ineffective traditional treatments.

 

Considering the uniqueness of Wang Fang’s disease, the team designed a compound dual-target CAR-T cell immunotherapy targeting both CD19 and BCMA. The success of this advanced therapy made Wang Fang the first case globally to be cured of lupus erythematosus using CAR-T cell therapy.

 

One month after treatment, she no longer needed wheelchair assistance; two months later, she could walk independently; and nine months later, besides the complete eradication of the tumor, the lupus erythematosus-related antibodies turned negative, leading to her clinical cure without relying on medication for her daily life.

 

Director Zhang Hongyu from the Blood Department of PKU Shenzhen Hospital stated that this successful case marks a significant breakthrough in CAR-T cell therapy, offering the possibility of cure to more patients. This successful clinical trial was also reported at the 61st American Society of Hematology (ASH) Annual Meeting, highlighting PKU Shenzhen Hospital’s significant contributions to the medical field.

 

After enduring this arduous battle, Wang Fang has regained her health and freedom. She expresses gratitude for the exceptional skills and selfless assistance of the medical team at PKU Shenzhen Hospital. Currently, for nine months, she has not taken any medication, regaining her beautiful hair and radiating vitality, looking forward to the future.

 

The appearance of this successful case brings hope and inspiration to the global medical community, showcasing the potential of CAR-T cell therapy in continuous exploration. The Blood Department team at PKU Shenzhen Hospital intends to continue exploring more effective and safer treatment approaches, bringing more hope for patients.

 

11 months ago CAR-T

The latest research findings of BCMA CAR-T therapy for multiple myeloma in 2023 | Equecabtagene Autoleucel (FUCASO)

The latest research findings of BCMA CAR-T therapy for multiple myeloma in 2023 | Equecabtagene Autoleucel (FUCASO®)

    IASO Bio and Innovent presented their latest research findings on the Equecabtagene Autoleucel injection (brand name: FUCASO®) for multiple myeloma at the 2023 American Society of Hematology (ASH) Annual Meeting. This study was primarily based on a post-hoc analysis of the FUMANBA-1 study, an Ib/II phase research assessing the efficacy and safety of this therapy in treating patients with relapsed and refractory multiple myeloma (RRMM).

    As of December 31, 2022, with a median follow-up of 18.07 months, deep and sustained responses were observed in 103 evaluable patients. Among these patients, the overall response rate (ORR) was 96.1%, and the stringent complete response/complete response (sCR/CR) rate was 77.7%. Among subjects without prior CAR-T therapy, the ORR reached 98.9%, the sCR/CR rate reached 82.4%, and the 12-month progression-free survival (PFS) rate was 85.5%.

Minimal residual disease (MRD) negativity rate is 94.2% in the total evaluable patients, and all patients who achieved CR or above were MRD negative. The median time to achieve MRD negativity was 15 days, with 80.8% of patients remaining MRD negative at 12 months post infusion.

In addition, Equecabtagene Autoleucel could persist in the body for an extended period of time the median duration was 307.5 days. 12 months after infusion, 50% of patients had a vector copy number (VCN) above the lower limit of detection; and 24 months after infusion, VCN could still be detected in 40% of the patients.

The research findings indicate a strong correlation between sustained MRD negativity and patient progression-free survival (PFS), along with the continuous presence of Equecabtagene Autoleucel in the body, which correlates positively with sustained MRD negativity.

The Equecabtagene Autoleucel injection may improve the long-term survival prospects of RRMM patients, offering enduring deep remission and holding significant importance for the sustained maintenance of MRD negativity in patients.

About Multiple Myeloma (MM)

Multiple Myeloma is a deadly blood cancer that often infiltrates the bone marrow causing anemia, kidney failure, immune problems, and bone fractures. For multiple myeloma patients, common first-line drug treatments include proteasome inhibitors, immunomodulatory drugs, and alkylating agents. While treatment may result in remission, most patients will inevitably enter the relapsed or refractory stage as there’s currently no cure. As a result, there is a significant unmet need for patients with relapsed/refractory multiple myeloma. In the United States, MM accounts for nearly 2% of all cancer cases, and more than 2% of cancer-related deaths.

According to Frost & Sullivan, the number of new MM cases in the United States rose from 30,300 in 2016 to 32,300 in 2020 and is expected to increase to 37,800 by 2025. Additionally, the total number of patients diagnosed with MM increased from 132,200 in 2016 to 144,900 in 2020 and is expected to rise to 162,300 by 2025. In China, the number of new MM cases rose from 18,900 in 2016 to 21,100 in 2020 and is expected to increase to 24,500 by 2025. The total number of patients diagnosed with MM in China increased from 69,800 in 2016 to 113,800 in 2020 and is expected to rise to 182,200 by 2025.

About Equecabtagene Autoleucel

Equecabtagene Autoleucel is an innovative fully-human anti-BCMA CAR-T cell therapy that uses lentivirus as a gene vector to transfect autologous T cells. The CAR comprises a fully-human scFv, CD8a hinge and transmembrane, as well as 4-1BB-mediated co-stimulation and CD3ζ activation domains. Through rigorous screening and comprehensive in vivo and in vitro evaluation, Equecabtagene Autoleucel has been proven to possess potent and rapid anti-myeloma activity, along with outstanding safety, efficacy, and persistence results.

Equecabtagene Autoleucel has received acceptance for New Drug Application (NDA) from China’s National Medical Products Administration (NMPA) for the treatment of RRMM and has obtained IND approval from the U.S. FDA. Additionally, the company was granted Breakthrough Therapy Designation (BTD) by the NMPA in February 2021, Orphan Drug Designation (ODD) in February 2022, and Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations from the FDA in February 2023. Besides multiple myeloma, NMPA has accepted its IND application for the new extended indication of Neuromyelitis Optica Spectrum Disorder (NMOSD). Innovent and IASO Bio are collaboratively developing Equecabtagene Autoleucel for the treatment of RRMM in mainland China.

About IASO Biotechnology

IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput chimeric antigen receptor T-cell (CAR-T) drug screening platform, and proprietary manufacturing processes, IASO Bio is developing a robust clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This pipeline comprises a diversified portfolio of over 10 novel products, including IASO’s flagship asset, Equecabtagene Autoleucel (CT103A), a fully human BCMA CAR-T injection.

In addition to Equecabtagene Autoleucel, the company’s pipeline includes the fully developed in-house human CD19/CD22 dual-targeted CAR-T cell therapy, which has received two IND clearances for treating relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL) and relapsed/refractory acute B-lymphoblastic leukemia (r/r B-ALL). CD19/CD22 is currently in Phase I clinical trials for r/r B-NHL. It was also granted ODD by the FDA in October 2021. In the approximately 20 patients dosed to date in the investigator-initiated trial, there were no immune effector cell-associated neurotoxicity syndrome (ICANS) observed in any patient, and the rate of grade 3 cytokine release syndrome (CRS) was less than 5%, with the remainder of patients experiencing no CRS or less than grade 3.

Leveraging its strong management team, innovative product pipeline, integrated manufacturing, and clinical capabilities, IASO aims to deliver transformative, curable, and affordable therapies that fulfill unmet medical needs to patients in China and around the world.

#BCMACART #EquecabtageneAutoleucel #FUCASO #ASH2023 #ClinicalResearch #Hematology #CARTtherapy #MRDnegative #CancerTreatment #MedicalInnovation #BloodCancer #OncologyResearch #DrugApproval #CellTherapy #CancerSurvival #FDAapproval #NMPAapproval #Biopharmaceutical #ClinicalTrials #MM

• 1
• 2